A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP

Фаза II рандомизированного контролируемого исследования S-аденозилметионина для снижения сывороточного α-фетопротеина у пациентов с циррозом печени при гепатите C и повышенным AFP
Timothy R.M. Morgan, Kathryn Osann, Teodoro Bottiglieri, Neville R. Pimstone, John Carl Hoefs, Ke‐Qin Hu, Tarek Hassanein, THOMAS D BOYER, Lorene Kong, Wen‐Pin Chen, Ellen S. Richmond, Rachel I. Gonzalez, Luz M. Rodriguez, Frank Louis Meyskens
2015-06-30

S-adenosylmethionine (SAMe)hepatitis C cirrhosisoxidative stress markersrandomized placebo-controlled trialα-fetoprotein (AFP)
In animal models of hepatocellular carcinoma (HCC), deficiency of S-adenosylmethionine (SAMe) increased the risk of HCC whereas administration of SAMe reduced HCC. The aim of this trial was to determine whether oral SAMe administration to patients with hepatitis C cirrhosis would decrease serum α-fetoprotein (AFP) level, a biomarker of HCC risk in hepatitis C. This was a prospective, randomized, placebo-controlled, double-blind trial of SAMe, up to 2.4 g/d, for 24 weeks as compared with placebo among subjects with hepatitis C cirrhosis and a mildly elevated serum AFP. Primary outcome was change in AFP between baseline and week 24. Secondary outcomes included changes in routine tests of liver function and injury, other biomarkers of HCC risk, SAMe metabolites, markers of oxidative stress, and quality of life. One hundred ten subjects were randomized and 87 (44 SAMe and 43 placebo) completed treatment. There was no difference in the change in AFP during 24 weeks among subjects receiving SAMe as compared with placebo. Changes in markers of liver function, liver injury, and hepatitis C viral level were not significantly different between groups. Similarly, SAMe did not change markers of oxidative stress or serum glutathione level. SAMe blood level increased significantly among subjects receiving SAMe. Changes in quality of life did not differ between groups. Overall, this trial did not find that SAMe treatment improved serum AFP in subjects with advanced hepatitis C cirrhosis and a mildly elevated AFP. SAMe did not improve tests of liver function or injury or markers of oxidative stress or antioxidant potential.
1
Blood SAMe levels increased significantly in subjects receiving SAMe, confirming systemic exposure without clinical biomarker effects.
2
In a randomized, double-blind, placebo-controlled 24-week Phase II trial, oral SAMe (up to 2.4 g/day) did not decrease serum AFP compared with placebo in hepatitis C cirrhosis patients with mildly elevated AFP.
3
Quality of life measures did not differ between SAMe and placebo groups.
4
SAMe did not change hepatitis C viral level, other biomarkers of HCC risk, markers of oxidative stress, or serum glutathione level compared with placebo.
5
SAMe treatment produced no significant differences versus placebo in routine liver function or liver injury tests over 24 weeks.

Oral S-adenosylmethionine (SAMe) treatment in patients with hepatitis C cirrhosis and mildly elevated serum α-fetoprotein

Effect of SAMe treatment on serum α-fetoprotein levels (primary) and on liver function/injury tests, other HCC-risk biomarkers, SAMe metabolites, oxidative stress markers, and quality of life (secondary) over 24 weeks

Publication Details
Publication Date
2015-06-30
Journal
Cancer Prevention Research
Publisher
American Association for Cancer Research
ISSN
1940-6215
Cited by
20
Access Type
Author Information
Authors
Timothy R.M. Morgan
Kathryn Osann
Teodoro Bottiglieri
Neville R. Pimstone
John Carl Hoefs
Ke‐Qin Hu
Tarek Hassanein
THOMAS D BOYER
Lorene Kong
Wen‐Pin Chen
Ellen S. Richmond
Rachel I. Gonzalez
Luz M. Rodriguez
Frank Louis Meyskens
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%